-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the team of Deng Yanhong of the Cancer Center of the Sixth Affiliated Hospital of Sun Yat-sen University (hereinafter referred to as "Zhongshan Sixth Hospital") completed a prospective phase III clinical study
The team demonstrated for the first time that for colorectal cancer patients receiving a moderate emetic chemotherapy (MEC) FOLFOX regimen, aprepitant instead of dexamethasone in combination with Palonosetron was more effective in preventing CINV
Dexamethasone is a glucocorticoid widely used to prevent and treat CINV
The relevant research results were recently published in eClinicalMedicine (IF=17.
In this study, the research team also exploratorily analyzed the changes in the number of peripheral blood cells before and after the first cycle of chemotherapy, and observed that the frequency of B cell decline in the DP group was more than that in the AP group, and the difference did not reach statistical significance (58.
All in all, in patients receiving the MEC regimen, aprepitant combined with Palonosetron was superior to dexamethasone plus parlonosesetron